# GLP-1 vs. Bariatric Surgery in Teens: What New Data Shows

Evidence & Research Status

Evidence LevelExtensive Human Clinical Data

FDA StatusNot FDA-approved for human use

Regulatory StatusResearch Use Only (RUO) — not for human consumption

Last UpdatedAugust 5, 2026

What This Article Covers

New GLP-1 bariatric surgery data published July 20, 2026 in JAMA Pediatrics shows a dramatic shift in how clinicians and families are treating adolescent obesity, with medication now displacing…

Primary References [JAMA Pediatrics](https://jamanetwork.com/journals/jamapediatrics/fullarticle/2851775) [ENDO 2026 meeting](https://www.endocrine.org/news-and-advocacy/news-room/2026/sontha-press-release-endo-2026)

Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use.

New GLP-1 bariatric surgery data published July 20, 2026 in [JAMA Pediatrics](https://jamanetwork.com/journals/jamapediatrics/fullarticle/2851775) shows a dramatic shift in how clinicians and families are treating adolescent obesity, with medication now displacing surgery as the default first-line approach for most younger patients.

*Note: this article discusses clinical treatment data that includes adolescents. Portal to Wellness does not market or sell products for pediatric or adolescent use and does not provide medical advice; see the full disclaimer at the end of this article.*

## What the New JAMA Pediatrics Data Shows

Researchers at UT Southwestern analyzed Epic Cosmos electronic health records for more than 204,000 patients ages 13 to 25 treated for obesity between May 2022 and January 2026 — the first national-scale analysis of its kind to characterize real-world use of [GLP-1 receptor](https://portaltowellness.net/glossary-glp-1-receptor/) agonists (GLP-1RAs) alongside metabolic and bariatric surgery (MBS) in this age group.

The trend line is stark. Exclusive GLP-1RA use rose from 88.2% of treated adolescents and young adults (May–November 2022) to 96.1% (June 2025–January 2026). Over the same window, bariatric surgery rates fell from 11.6% to 3.7%. The share of patients combining both approaches held essentially flat at 0.2% throughout the study period — researchers did not observe growing interest in a combined strategy, just a near-total swap from surgical to pharmacological first-line treatment.

## Where Adolescent Obesity Treatment Stood in 2022 vs. 2026

| Approach | May–Nov 2022 | Jun 2025–Jan 2026 |
| --- | --- | --- |
| Exclusive GLP-1RA use | 88.2% | 96.1% |
| Bariatric surgery (MBS) | 11.6% | 3.7% |
| Combined GLP-1RA + MBS | 0.2% | 0.2% |

*Source: UT Southwestern / [JAMA Pediatrics](https://jamanetwork.com/journals/jamapediatrics/fullarticle/2851775) , Epic Cosmos analysis of 204,000+ patients ages 13–25, published July 20, 2026.*

## From One-Time Fix to Ongoing Management: The Restart Data

A separate dataset, presented at the Endocrine Society’s [ENDO 2026 meeting](https://www.endocrine.org/news-and-advocacy/news-room/2026/sontha-press-release-endo-2026) in June, adds context for why this shift matters beyond adolescents specifically. Researchers tracked GLP-1 prescription claims for roughly 60,000 U.S. adults ages 18–64 with type 2 diabetes who had used liraglutide, [semaglutide](https://portaltowellness.net/shop/semaglutide-5mg-vial-research-use-only/) , or [tirzepatide](https://portaltowellness.net/shop/tirzepatide-60mg-10-vial-pack/) between 2019 and 2025. About 40% had discontinued their medication within the first year, and nearly 60% had stopped by the two-year mark — but reinitiation was common: more than half of those who stopped restarted within a year, and nearly two-thirds had restarted within two years.

Tirzepatide users were 41% less likely to discontinue than those on older liraglutide, and semaglutide users were 28% less likely to discontinue than liraglutide users. Patients on Medicaid or Medicare, Black patients, and the more than one-third of patients who reported nausea or other GI side effects were more likely to discontinue within the first year.

Taken together, researchers describe a pattern that looks less like a finite course of treatment and more like chronic-disease management: patients cycle on and off GLP-1RAs, and the majority who stop end up restarting rather than staying off long-term.

## Why Researchers Are Watching Discontinuation Patterns Closely

The ENDO 2026 discontinuation data matters for a second reason beyond adherence statistics: it reframes how researchers think about GLP-1 exposure duration. If most patients who stop a GLP-1RA restart within a year, then a meaningful share of the population isn’t taking these compounds for a defined 12- or 24-week course — they’re accumulating years of cumulative, intermittent exposure with gaps of unknown length in between. That pattern hasn’t been the basis for most existing long-term safety and efficacy research, which typically studies continuous use over a fixed trial period.

The demographic skew in who discontinues is also worth noting for researchers designing future studies: patients on Medicaid or Medicare and Black patients discontinued at higher rates in the ENDO 2026 dataset, alongside the more than one-third of patients who cited GI side effects. Left unexamined, a research base drawn primarily from patients who tolerate and afford continuous therapy could understate how side effects, cost, and access barriers to GLP-1RAs shape real-world outcomes for the wider population — including the same population, of adolescents and young adults, driving the shift documented in the JAMA Pediatrics data above.

## Open Questions for Researchers

The shift toward GLP-1RAs as the default first-line approach in adolescents raises questions the current data can’t yet answer. What happens to muscle and bone development during the years GLP-1RAs are used through adolescence and into adulthood? How does the high one- and two-year restart rate observed in adults translate to a population that may be on therapy for a decade or more? Does earlier medication use change the trajectory of surgical candidacy later in life, and does discontinuation followed by weight regain differ by how early treatment started? Long-term adherence, fertility considerations, and outcomes after eventual discontinuation all remain open areas of study.

*All compounds referenced in this article are available for research use only. Portal to Wellness does not market or sell products for use in minors, and nothing in this article should be read as guidance for pediatric or adolescent use. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.*

### Continue Your Research

Related Articles [Wegovy Pill Total Monthly Cost, Explained](https://portaltowellness.net/research/wegovy-pill-total-monthly-cost/) [GLP-1 Prior Authorization Data](https://portaltowellness.net/research/glp-1-prior-authorization-data/)

Related Products [PTW Daily Essentials Kit — Creatine, Electrolytes and Magnesium](https://portaltowellness.net/shop/ptw-daily-essentials-kit/) [Semaglutide – 5mg/vial — Research Use Only](https://portaltowellness.net/shop/semaglutide-5mg-vial-research-use-only/) [Tirzepatide – 60mg/vial (Research Use Only)](https://portaltowellness.net/shop/tirzepatide-60mg/)

Related Research Guide [GLP-1 & Metabolic Research Guide](https://portaltowellness.net/metabolic-research-kit/)

Related Category [GLP-1 & Metabolic Research Guide](https://portaltowellness.net/metabolic-research-kit/)

Related FAQ [General Research & Ordering FAQ](https://portaltowellness.net/faq/)

More Research [Browse the full PTW Research Hub →](https://portaltowellness.net/research/)

---

Source: https://portaltowellness.net/research/glp-1-bariatric-surgery-teens/
Research use only. Terms: https://portaltowellness.net/research-use-only/